Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
Public ClinicalTrials.gov record NCT05119686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients
Study identification
- NCT ID
- NCT05119686
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- AR882 Dose 1 Drug
- AR882 Dose 2 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2021
- Primary completion
- Nov 16, 2022
- Completion
- Nov 16, 2022
- Last update posted
- May 11, 2023
2021 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arthrosi Investigative Site | Gilbert | Arizona | 85297 | — |
| Arthrosi Investigative Site | Sun City | Arizona | 85351 | — |
| Arthrosi Investigative Site | Tucson | Arizona | 85704 | — |
| Arthrosi Investigative Site | Miami | Florida | 33143 | — |
| Arthrosi Investigative Site | Miami Lakes | Florida | 33014 | — |
| Arthrosi Investigative Site | Tampa | Florida | 33613 | — |
| Arthrosi Investigative Site | Honolulu | Hawaii | 96814 | — |
| Arthrosi Investigative Site | Overland Park | Kansas | 66212 | — |
| Arthrosi Investigative Site | Cleveland | Ohio | 44122 | — |
| Arthrosi Investigative Site | Cleveland | Ohio | 44195 | — |
| Arthrosi Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Arthrosi Investigative Site | Dallas | Texas | 75231 | — |
| Arthrosi Investigative Site | Houston | Texas | 77074 | — |
| Arthrosi Investigative Site | Tomball | Texas | 77375 | — |
| Arthrosi Investigative Site | West Jordan | Utah | 84088 | — |
| Arthrosi Investigative Site | Glendale | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05119686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2023 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05119686 live on ClinicalTrials.gov.